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Variably protease-sensitive prionopathy (VPSPr) can 
occur in persons of all codon 129 genotypes in the human 
prion protein gene (PRNP) and is characterized by a unique 
biochemical profile when compared with other human prion 
diseases. We investigated transmission properties of VPSPr 
by inoculating transgenic mice expressing human PRNP 
with brain tissue from 2 persons with the valine-homozygous 
(VV) and 1 with the heterozygous methionine/valine codon 
129 genotype. No clinical signs or vacuolar pathology were 
observed in any inoculated mice. Small deposits of prion 
protein accumulated in the brains of inoculated mice after 
challenge with brain material from VV VPSPr patients. Some 
of these deposits resembled microplaques that occur in the 
brains of VPSPr patients. Comparison of these transmission 
properties with those of sporadic Creutzfeldt-Jakob disease 
in the same lines of mice indicated that VPSPr has distinct 
biological properties. Moreover, we established that VPSPr 
has limited potential for human-to-human transmission.
Human prion diseases, also called transmissible spongi-form encephalopathies, are a group of rare and inevi-
tably fatal neurodegenerative diseases. Prion diseases are 
unique in that they occur as idiopathic (sporadic), familial, 
and acquired disorders. The sporadic form of Creutzfeldt-
Jakob disease (sCJD) accounts for >80% of all human 
prion diseases. Six subtypes of sCJD have been classified 
according to the prion protein (PrP) genotype at codon 129 
(methionine [M]/M, M/valine [V], VV) and the biochemi-
cal profile of the protease-resistant core of the abnormal 
disease-specific PrP (PrPres) (PrPres type 1 or PrPres type 2A 
or 2B) (1,2). Experimental transmission of brain tissue from 
patients of these 6 different sCJD subtypes into 3 transgenic 
mouse lines expressing different human prion protein gene 
PRNP sequences (coding for 129MM, MV, and VV) has 
identified 4 distinct strains of the CJD agent (3).
In 2008, a novel prion disease, initially referred to as 
protease-sensitive prionopathy, was reported in 11 patients 
who had been referred to the National Prion Disease Pa-
thology Surveillance Center (Cleveland, OH, USA) during 
May 2002–January 2006. All 11 patients were of the PRNP 
codon 129VV genotype, and postmortem examination of 
brain tissues showed that the patients had a spongiform en-
cephalopathy (4). As with patients with sCJD, these patients 
had no mutations in the PRNP coding region, and no risk 
factors for the development of iatrogenic CJD were identi-
fied among the patients. The defining feature of this group 
of patients was the unusual biochemical properties of the 
abnormal PrP in the brain. Compared with the biochemical 
properties of PrPres in sCJD, the PrPres in VPSPr was found 
to be much less resistant to protease digestion. VPSPr PrPres 
shows a faint ladder-like appearance of protease-resistant 
fragments on Western blot and a prominent low–molecular 
weight fragment of ≈8 kDa. The neuropathologic features 
in this group were also unusual, in particular, the accumula-
tion of microplaques within the cerebellum and thalamus, 
which stained intensely for PrP.
Since the original description of those 11 cases, 19 ad-
ditional cases have been reported, including some in pa-
tients of the PRNP codon 129MM and 129MV genotypes 
(5–7). Although case numbers remain low, the prevalence 
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of this novel prion disease appears to vary according to the 
codon 129 genotype of affected persons: 62% of reported 
cases have been detected in persons of the PRNP codon 
129VV genotype. In comparison, 17% of sCJD cases and 
only 12% of the general white population are of the PRNP 
codon 129VV genotype (8,9). Subsequent studies showed 
differences between the 3 codon 129 genotypes in protease 
digestion sensitivity of the abnormal PrP in the brain. This 
difference in protease sensitivity has resulted in the condi-
tion being renamed variably protease-sensitive prionopathy 
(VPSPr) (10).
The presence of PrPres in VPSPr suggests that PrP 
plays a central role in the disease process. However, the re-
lationship between different forms of PrP and prion disease 
has not been established. It is possible that the protease-
sensitive and the truncated forms of the abnormal PrP may 
contribute to the unique neuropathology of VPSPr and may 
also influence the potential for transmission of disease to 
other persons.
Human-to-human transmission of prion diseases is of 
great concern for public health reasons (11–13). The use 
of gene-targeted transgenic mice expressing human PrP 
enables the direct comparison of transmission properties 
by using well-defined strains of sCJD and variant CJD 
(vCJD). Moreover, this system enables the prediction of 
disease transmission between persons and has been used 
extensively to predict the potential for human-to-human 
spread of sCJD and vCJD (3,14–16). In this study, we chal-
lenged human PrP–expressing transgenic mice with brain 
tissue from 3 persons with VPSPr and directly compared 
the data with those from previous sCJD transmission exper-
iments in these mouse lines. Thus, we determined whether 
any biological similarities exist between these apparently 
different prion diseases. Furthermore, these transmissions 
enabled an assessment of the potential for human-to-human 
transmission of VPSPr.
Methods
Human Tissues
Frozen brain tissues from 3 patients with VPSPr were 
investigated in this transmission series. Tissues analyzed 
were obtained from 2 patients who originated from the 
United Kingdom: 1 patient had the PRNP codon 129VV 
genotype (patient UK-VV), and the other had the 129MV 
genotype (patient UK-MV). The third patient originated 
from the Netherlands and had the PRNP codon 129VV 
genotype (patient NL-VV). The clinical, neuropathologic 
and PrP biochemical features of these cases have been de-
scribed in detail elsewhere (5,6,17). Patient details for the 
3 cases, including age, sex, neuropathologic features, and 
PrPres type, are summarized in Table 1. As reference stan-
dards in Western blot experiments, we used frozen brain 
tissues in which the 8-kDa and the 2A PrPres types were 
readily detectable; the tissues were from patients with 
typical UK cases of sCJD (subtypes MM1, MM2, VV1, 
and VV2) and from another UK patient (codon 129VV) 
with VPSPr.
Consent and ethical approval for the retention and use 
of these materials for research was obtained by the Lo-
thian NHS Board Research Ethics Committee (Reference: 
LREC/2000/4/157). Material was sourced through The Ed-
inburgh Brain Bank (Scotland, UK).
Gray matter–enriched frontal cortex tissue samples 
(≈250 mg) had been obtained at autopsy from each of the 
3 persons in our study. The samples were homogenized at 
a 10% (wt/vol) concentration in sterile physiologic saline 
and stored at –20°C until use. Before being inoculated into 
mice, the homogenates were further diluted to a 1% (wt/
vol) concentration in sterile physiologic saline.
Experimental Animals
Mice from 3 lines of transgenic mice expressing hu-
man PrP (designated HuMM, HuMV, and HuVV, accord-
ing to the PRNP codon 129 genotype) were challenged 
in this transmission series (15). Mice were anesthetized 
and inoculated intracerebrally with 20 μL of a 1% brain 
homogenate. Beginning on postinoculation day 100, the 
mice were scored on a weekly basis for clinical signs of 
neurologic disease, as described by Fraser and Dickinson 
(18). Mice were humanely killed at the clinical endpoint 
for prion disease or at the end of the animal’s full life span. 
Incubation periods were calculated as the number of days 
between brain-tissue inoculation and the clinical endpoint, 
when mice showed unequivocal neurologic disease. In 
the absence of an incubation period, the survival time (in 
days) was calculated. Brains were removed from the mice 
postmortem and sagittally sectioned; half of the brain was 
snap-frozen for biochemical analysis, and the other half 
was fixed in 10% formal saline for histologic analysis. 
These animal experiments were approved by The Roslin 
Institute’s (University of Edinburgh) Animal Welfare and 
Ethical Review Committee and conducted according to the 
regulations of the UK Home Office Animals (Scientific 
Procedures) Act 1986.
Scoring of Vacuolation
Mouse brains for histologic analysis were fixed in for-
mal saline for a minimum of 48 h before being immersed 
in 96% formic acid for 1.5 h to reduce the titer of the infec-
tious agent. Brains were trimmed coronally into 5 standard 
rostrocaudal levels, resulting in 5 brain slices. Tissues were 
then embedded in paraffin wax and cut into serial 5-μm sec-
tions. A single section from all inoculated mice was stained 
with hematoxylin and eosin to determine the presence and 
severity of disease-specific vacuolation in 9 standard gray 
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matter regions and 3 white matter regions, a protocol re-
ferred to as lesion profiling (18).
Immunohistochemistry
Immunohistochemical analysis for PrP was performed 
by using 4 PrP monoclonal antibodies that recognize differ-
ent residues of the PrP: 1) 3F4/epitope: aa 109–112 (Cam-
bridge Bioscience, Cambridge, UK); 2) 12F10/epitope: 
aa 142–160 (Bioquote Ltd, York, UK); 3) 6H4/epitope: 
aa 144–152 (Prionics AG, Schlieren, Switzerland); and 
4) monoclonal antibody KG9/aa140–180 (TSE Resource 
Centre, The Roslin Institute). In brief, 5-μm paraffin-em-
bedded tissue sections were autoclaved at 121°C in dis-
tilled water for 10 min and then immersed in 96% formic 
acid for 10 min. Sections were immersed in proteinase K 
solution (5 μg/mL) for 10 min and then blocked for 20 min 
in normal rabbit serum, after which they were incubated 
overnight at room temperature with the primary antibodies 
(3F4, 5 μg/mL; 6H4, 500 ng/mL; 12F10, 30 ng/mL; and 
KG9, 40 ng/mL). After overnight incubation, sections were 
incubated for 1 h in an anti-mouse biotinylated antibody 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA, USA), and then immunolabeling was completed by us-
ing a VECTASTAIN Elite ABC Kit (Vector Laboratories, 
Burlingame, CA, USA). Staining was then visualized by 
using 3,3′-diaminobenzidine chromogen.
The presence of gliosis was assessed by incubating tissue 
sections with Polyclonal Rabbit Anti-Cow Glial Fibrillary 
Acidic Protein (Dako, Ely, UK) for 1 h at room temperature. 
Sections were then incubated for 1 h at room tempera-
ture with an anti-rabbit biotinylated antibody (Jackson 
ImmunoResearch Laboratories, Inc.) before the immuno-
labeling was completed by using a VECTASTAIN Elite 
ABC Kit. Staining was then visualized by using 3,3′-di-
aminobenzidine chromogen.
Thioflavin-S Visualization
Paraffin-embedded tissue sections were immersed in 
hematoxylin solution for 1 min and rinsed in running wa-
ter before being immersed in Scott’s tap water for 30 s. 
Sections were then immersed in 1% Thioflavin-S (Sigma, 
Gillingham, UK) for 5 min, followed by 3 dips in 70% 
alcohol. Tissue sections were then rinsed well in water 
and mounted.
Biochemical Studies of Brain Samples
The method we used for studying brain tissues was 
based on our previous Western blotting technique (19). 
For analysis, 10% (wt/vol) brain tissue homogenates were 
prepared by homogenization of brain material in 9 vol-
umes (wt/vol) of Tris-buffered saline, pH 7.6, containing 
0.5% Nonidet P40 and 0.5% sodium deoxycholate. Ali-
quots of the cleared 10% brain homogenates were subject-
ed to limited proteolysis by digestion with proteinase K 
(50 μg/mL) for 1 h at 37°C. The reaction was terminated 
by the addition of Pefabloc SC (Roche, Burgess Hill, UK) 
to a final concentration of 1 mM/L. Proteinase K–treated 
and non–proteinase K–treated samples (5 μL) were ana-
lyzed by Western blot. Polyacrylamide gel electrophoresis 
and Western blotting were performed by using NuPAGE 
Novex 10% Bis-Tris Protein Gels, 1.0 mm, (Life Technol-
ogies, Paisley, UK) as previously described (19). The gel 
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Table 1. Characteristics of patients with variably protease-sensitive prionopathy whose brain samples were selected for transmission 
studies* 
Patient, 
sex 
Age at 
death, y 
Disease 
duration, 
mo 
Clinical signs and 
symptoms Neuropathologic features PrPres type 
NL-VV, 
M† 
57 20 Progressive dementia, 
spastic paraplegia, 
sensorimotor 
polyneuropathy 
Mild to moderate spongiform change in basal 
ganglia, and cerebral and cerebellar cortices. 
Coarse granular deposits of PrP in cerebral 
cortex, basal ganglia, and thalamus. PrP 
microplaques present within molecular layer of 
cerebellar cortex 
Faint ladder-like 
appearance of protease-
resistant fragments with a 
prominent low–molecular 
weight fragment 
UK-VV, 
F‡ 
59 42 Progressive dementia, 
emotional and 
obsessive behavior 
(early), very occasional 
myoclonus (late) 
Mild to moderate spongiform change in basal 
ganglia, thalamus, and cerebral and cerebellar 
cortices. Widespread granular accumulations of 
PrP in all brain regions. PrP microplaques present 
within molecular layer of cerebellar cortex 
Faint, ladder-like 
appearance of protease-
resistant fragments with a 
prominent low–molecular 
weight fragment 
UK-MV, 
M§ 
76 12 Forgetfulness, 
visuospatial perceptual 
problems, difficulties 
walking, action tremor, 
akinetic mutism 
Spongiform change most prominent in the frontal 
cortex. PrP microplaques, synaptic and granular 
accumulations of PrP restricted to cerebral cortex, 
basal ganglia, and thalamus. Diffuse Lewy body 
and tau pathology observed, with 
amyloid-β plaques and a widespread amyloid 
angiopathy 
Faint ladder-like 
appearance of protease-
resistant fragments 
including a low–
molecular weight 
fragment 
*PrP, prion protein; PrPres, protease-resistant isoform of the disease-specific PrP. 
†NL-VV, patient from the Netherlands who was homozygous for valine at codon 129 of the PrP gene (PRNP). Case report, Jansen et al. (6). 
‡UK-VV, patient from the United Kingdom who was homozygous for valine at PRNP codon 129. Case report, Head et al. (5). 
§UK-MV, patient from the United Kingdom who was heterozygous for methionine/valine at PRNP codon 129. Case report, Head et al. (17). 
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electrophoresis time was abbreviated to retain low–mo-
lecular mass proteins (5,6). The proteins were transferred 
onto Hybond-P PVDF membrane (GE Healthcare Life 
Sciences, Amersham, UK). Immunodetection of PrP was 
carried out by using monoclonal antibody 3F4 (Millipore, 
Watford, UK) at a final concentration of 75 ng/mL for 1 h. 
For comparison, immunodetection of PrP on proteinase 
K–treated extracts was carried out by using monoclonal 
antibody 1E4 (provided by J. Langeveld) at a final con-
centration of 1 μg/mL (6). The secondary antibody was 
ECL Anti-mouse IgG, peroxidase-linked species-specific 
F(ab′)2 fragment (from sheep) (GE Healthcare Life Sci-
ences), used at a concentration of 1/25,000 for 1 h. Am-
ersham ECL Prime Western Blotting Detection Reagent 
(GE Healthcare Life Sciences) was used for detection of 
proteins. The blots were exposed to ECL Hyperfilm (GE 
Healthcare Life Sciences) for various amounts of time or 
were analyzed by using the ChemiDoc XRS+ System with 
Image Lab Software (Bio-Rad, Hemel Hempstead, UK).
Results
Biochemical Analysis of Brain Tissue  
from VPSPr Patients
We performed Western blot analysis on extracts of ho-
mogenates prepared from brain samples from all 3 VPSPr 
patients. For comparison, we ran these extracts alongside 
extracts of homogenates prepared from brain samples from 
4 sCJD patients (sCJD subtypes MM1, MM2, VV1, and 
VV2) representing each of the 4 distinct strains of sCJD 
agent, as identified by transmission to transgenic mice (3). 
Western blotting was performed with and without protein-
ase K digestion by using the PrP antibody 3F4 (Figure 1). 
In the absence of proteinase K digestion, extracts from the 3 
VPSPr patients showed a similar relative load of PrP when 
compared with extracts from sCJD patients (Figure 1, panel 
B). After the sCJD and VPSPr extracts were digested with 
proteinase K, their biochemical profiles and PrPres loads 
differed (Figure 1, panel A). The biochemical profile of the 
extracts prepared from brain tissue from patients UK-VV 
and NL-VV VPSPr showed a single low–molecular weight 
fragment (<10 kDa), characteristic of VPSPr. In the extract 
from the UK-MV case, this low–molecular weight frag-
ment was detected in addition to a faint ladder-like pattern 
of PrPres fragment.
Increased sensitivity in the detection of PrP fragments 
by Western blotting using the monoclonal antibody 1E4 
has been reported in cases of VPSPr (4,10). In this study, a 
direct comparison of the detection sensitivity of 2 PrP an-
tibodies (monoclonal antibodies 1E4 and 3F4) was carried 
out by Western blot by using brain homogenate from all 3 
VPSPr patients in the transmission series. Consistent with 
our previous findings (5,6), we found no increase in the 
PrP detection sensitivity by using 1 antibody or the other 
(Figure 2).
Absence of Clinical Disease and Vacuolar Pathology
No evidence of clinical disease with vacuolar pathol-
ogy was observed in any of the 133 mice inoculated in this 
transmission series (Table 2). Furthermore, no vacuolar 
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Figure 1. Western blot analysis of protease-resistant isoforms of PrP 
(PrPres) in extracts of frontal cortex tissue prepared from postmortem 
samples from 4 persons with sCJD and from 3 persons with VPSPr 
whose brain samples were used for experimental transmission 
studies in transgenic mice. Results are shown for extracts treated 
(A) and not treated (B) with proteinase K. All lanes were loaded with 
5.0 μL of 10% (wt/vol) brain homogenate, except lanes 9 and 10 in 
(A), which were loaded with 1.5 μL and 20.0 μL, respectively. Blots 
were probed with Anti-Prion Protein Antibody monoclonal antibody 
3F4 (Millipore, Watford, UK). Lane 1, molecular weight marker 
(sizes indicated at left in kDa); lane 2, sCJD subtype MM1; lane 
3, sCJD subtype MM2; lane 4, sCJD subtype VV1; lane 5, sCJD 
subtype VV2; lane 6, VPSPr UK-VV; lane 7, VPSPr UK-MV; lane 8, 
VPSPr NL-VV; lane 9, diagnostic reference sample (sCJD subtype 
VV2); lane 10, diagnostic reference sample (VPSPr VV). MM, 
homozygous for methionine; MV, heterozygous for methionine/
valine; NL-VV, patient from the Netherlands who had VPSPr and 
the codon 129VV genotype; sCJD, sporadic Creutzfeldt-Jakob 
disease; UK-VV and UK-MV, patients from the United Kingdom 
who had VPSPr and the codon 129VV and 129MV genotypes, 
respectively; VPSPr, variably protease-sensitive prionopathy; VV, 
homozygous for valine.
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pathology was observed in any of the asymptomatic mice 
in the study. Clinical neurologic signs were observed 
on a few occasions without pathologic confirmation of 
prion disease, suggesting a nontransmissible spongiform 
encephalopathy condition related to the age of the mice 
in the study.
Minimal PrP Deposition in Restricted Brain Regions
Immunohistochemical analysis for PrP in mice chal-
lenged with brain homogenate prepared from VPSPr patient 
UK-MV showed no evidence of PrP accumulation within 
the brain of inoculated mice. Immunohistochemical analy-
sis for PrP in mice challenged with homogenate prepared 
from the brain of patient NL-VV showed PrP accumulation 
in 7 of 14 HuVV and 3 of 15 HuMV transgenic mice, but 
no PrP deposition was found in the HuMM mice (Table 2). 
PrP deposits were detected most frequently with the PrP 
antibodies 6H4 and 3F4 and less frequently with antibodies 
KG9 and 12F10. This differential labeling is similar to that 
reported in human cases of VPSPr and may be related to 
the conformation of VPSPr-associated PrP and the avail-
ability of the epitopes that the antibodies detect (5,17,20). 
The pattern of PrP accumulation was limited to small, of-
ten numerous, focal plaque-like deposits located within the 
corpus callosum and the stratum oriens and stratum lacu-
nosum moleculare of the hippocampus and parallel to the 
lateral ventricle (Figure 3, panels A–C). Sections treated 
with Thioflavin-S confirmed that these plaque-like deposits 
in the corpus callosum and its vicinity were composed of 
amyloid (Figure 3, panel D).
In mice challenged with a homogenate prepared from 
the brain of patient UK-VV, 5 of 14 HuVV, 2 of 14 HuMV, 
and 1 of 15 HuMM mice showed evidence of PrP deposits 
(Table 2). HuVV and HuMV mice showed PrP deposits 
similar to those found in the mice challenged with extract 
prepared from the brain of patient NL-VV, with 1 excep-
tion: a single HuVV mouse showed plaque-like accumula-
tions and a pattern of intensely stained, small, round gran-
ules surrounded by fine target-like punctate staining within 
the CA3 region of the hippocampus and hippocampal fis-
sure (Figure 4, panels A–C). The larger granular deposits 
resembled the microplaque accumulations found within 
the molecular layer of the cerebellum (Figure 4, panel D), 
hippocampal formation, basal ganglia, and thalamus in hu-
mans with VPSPr (5). The PrP-positive granules within the 
hippocampus stained most intensely with antibodies 3F4 
and 12F10 and less intensely with antibodies KG9 and 
6H4; this finding was similar to that observed in brains of 
patients with VPSPr (5,6,17) (Figure 4).
No PrPres Detected by Biochemical Analysis
Western blot analysis was performed on frozen brain 
tissue from 6 HuVV mice challenged with brain homoge-
nate from VPSPr patient UK-VV. Immunohistochemistry 
results showed that 4 of the 6 mice had small, plaque-like 
deposits within the corpus callosum, and 1 of the 4 mice 
also had microplaque-like deposits in the hippocampus. 
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 Figure 2. Western blot analysis of PrPres in extracts of frontal cortex 
tissue prepared from postmortem samples from 2 persons with sCJD 
(subtypes MM1 and VV2) and the 3 persons with VPSPr whose 
brain samples were used for experimental transmission studies in 
transgenic mice (patients NL-VV, UK-VV, and UK-MV). Extracts 
from another patient who had VPSPr of UK origin (codon 129VV 
genotype) was also included on the blot (lane 6). Duplicate blots were 
probed with the following monoclonal antibodies: Anti-Prion Protein 
Antibody monoclonal antibody 3F4 (Millipore, Watford, UK) (A) and 
1E4 (provided by J. Langeveld) (B). The 2 antibodies detected PrPres 
equally well in extracts from persons with sCJD or with VPSPr. All 
lanes were loaded with 5 μL of a 10% (wt/vol) brain homogenate. 
Brain homogenates were analyzed after digestion with Proteinase K. 
Lane 1, molecular weight marker (sizes indicated at left in kDa); lane 
2, sCJD MM1; lane 3, VPSPr UK-VV; lane 4, VPSPr UK-MV; lane 5, 
VPSPr NL-VV; lane 6, additional VPSPr of UK origin; lane 7, sCJD 
VV2. MM, homozygous for methionine; PrPres, protease-resistant 
isoform of the disease-specific prion protein; NL-VV, patient from the 
Netherlands who had VPSPr and the codon 129VV genotype; sCJD, 
sporadic Creutzfeldt-Jakob disease; UK-VV and UK-MV, patients 
from the United Kingdom who had VPSPr and the codon 129VV and 
129MV genotypes, respectively; VPSPr, variably protease-sensitive 
prionopathy; VV, homozygous for valine.
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Neuropathologic examination of the remaining 2 mice 
showed no evidence of transmission. Four noninoculat-
ed HuVV mice were included as negative controls. No 
disease-specific banding was observed in any of the mice 
(data not shown); this finding is consistent with the ex-
tremely low levels of PrP deposition detected by immu-
nohistochemistry.
Astrocytic Reactivity Associated with  
a Single Transmission 
HuVV mice were examined for evidence of astrocytic 
gliosis. In mice showing only plaque-like deposits of PrP, 
there was no association between astrocytosis and PrP 
deposition and no evidence of reactive astrocytosis (Figure 
5). In contrast, in the HuVV mice inoculated with brain 
homogenate from patient UK-VV, a single mouse showed 
reactive astrocytosis in the vicinity of the microplaque-like 
deposits (Figure 5). This HuVV mouse is the same mouse 
that showed evidence of plaque-like and microplaque-like 
deposits similar to those found in humans with VPSPr.
Discussion
The inoculation of homogenates prepared from the 
brains of 3 patients with VPSPr (UK-MV, UK-VV and 
NL-VV) into transgenic mice expressing the differ-
ent forms of the human PrP gene has resulted in very 
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Table 2. Results of intracerebral inoculation of brain tissue homogenates from 3 patients with variably protease-sensitive prionopathy 
into 3 lines of human transgenic mice* 
Brain inoculum source, 
mouse line† 
No. mice positive/no. total Mean no. PrP plaque–like 
deposits (range)¶ Clinical signs of prion disease‡ Vacuolar degeneration‡ PrP deposition§ 
UK-VV     
 HuMM 0/15 0/15 1/15 0# 
 HuMV 4/15 0/15 2/14 5 (2–8) 
 HuVV 0/14 0/14 5/14 10 (1–17) 
UK-MV     
 HuMM 1/15 0/15 0/15 0 
 HuMV 1/15 0/15 0/15 0 
 HuVV 0/15 0/15 0/15 0 
NL-VV     
 HuMM 0/15 0/15 0/15 0 
 HuMV 0/15 0/15 3/15 8 (1–15) 
 HuVV 0/14 0/14 7/14 3 (2–4) 
*HuMM, HuMV, and HuVV, transgenic mice expressing the different forms of the human PrP gene (i.e., those homozygous for methionine [MM] or valine 
[VV] or heterozygous for methionine and valine [MV]); PrP, prion protein. 
†Brain inoculum was prepared from postmortem samples from persons with variably protease-sensitive prionopathy. NL-VV, patient from the Netherlands 
who had the PrP codon 129VV genotype; UK-MV, patient from the United Kingdom who had the PrP codon 129MV genotype; UK-VV, patient from the 
United Kingdom who had the PrP codon 129VV genotype. 
‡In mice with a positive score for clinical signs of a prion disease and a negative score for vacuolar pathology, the neuropathologic assessment was 
considered definitive. 
§A positive score for PrP pathology was given to mice showing PrP deposition in the brain with at least 1 of the 4 PrP antibodies used in the 
immunohistochemical analysis. 
¶The number of plaque-like deposits was counted per mouse, and results are given as mean (range) for each genotype. 
#Mouse showed evidence of PrP deposition in a tumor. 
 
 
Table 3. Results of intracerebral inoculation of brain tissue homogenates from 4 patients with different subtypes of the sporadic form of 
Creutzfeldt-Jakob disease into 3 lines of human transgenic mice* 
Brain inoculum source, 
mouse line† 
No. mice positive/no. total 
Clinical signs of prion disease Vacuolar degeneration PrP deposition 
MM1    
 HuMM 10/13 13/13 13/13 
 HuMV 9/14 14/14 14/14 
 HuVV 8/16 13/16 14/16 
MM2    
 HuMM 0/16 0/16 0/15 
 HuMV 0/18 0/18 2/18 
 HuVV 0/17 0/17 3/17 
VV1    
 HuMM 0/16 0/16 2/16 
 HuMV 2/14 9/14 1/14 
 HuVV 2/14 7/14 7/14 
VV2    
 HuMM 4/18 6/18 15/17 
 HuMV 1/15 5/15 12/14 
 HuVV 13/16 16/16 15/15 
*Data adapted from Bishop et al. (3). HuMM, HuMV, and HuVV, transgenic mice expressing the different forms of the human PrP gene (i.e., those 
homozygous for methionine [MM] or valine [VV] or heterozygous for methionine and valine [MV]). PrP, prion protein. 
†Brain inoculum was prepared from postmortem samples from persons who had the MM1, MM2, VV1, or VV2 subtype of sporadic Creutzfeldt-Jakob 
disease. 
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different transmission properties when compared with 
those of previously characterized sCJD strains (3). No 
clinical disease or vacuolar pathology was observed in 
any of the mice. The only evidence for transmission of 
disease was the neuropathologic finding of abnormal PrP 
accumulation in the form of microplaque-like and granu-
lar deposits in the hippocampus and subventricular areas 
of the brain. These results contrast considerably with 
those observed with sCJD in the same HuMM/HuMV/
HuVV mouse lines (3). Sporadic CJD transmits to all 
these mouse lines, as indicated by evidence of clinical 
signs and vacuolar pathology and/or PrP deposition, and 
the combination of these transmission properties has re-
sulted in the identification of 4 strains of sCJD (3). Of the 
4 sCJD strains, subtype VV2 showed the greatest frequen-
cy of clinical (13/16), vacuolar (16/16), and pathologic 
(15/15) signs of prion disease following inoculation into 
HuVV mice (Table 3) (3). In contrast, the MM2 subtype 
of sCJD showed the least transmission to the mice: no 
mice had clinical signs or vacuolar pathology, and only 
3 of 17 HuVV and 2 of 18 HuMV mice had evidence of 
PrP deposition in the form of small punctate deposits in 
the thalamus (Table 3) (3). Although this transmission 
of the MM2 subtype might be considered similar to that 
of VPSPr, the PrP deposition differed in form and brain 
area compared with the deposition observed in the VPSPr 
studies. Unlike sCJD, which shows transmission from pa-
tients with all 3 codon 129 genotypes, only VPSPr from 
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Figure 3. Neuropathology in transgenic mice following inoculation with brain homogenate prepared from a postmortem sample from a 
person with VPSPr. Numerous PrP-labeled plaque-like deposits within the corpus callosum of HuVV (A) and HuMV (B) mice inoculated 
with brain homogenate from patient UK-VV. C) A single small PrP-labeled plaque in the stratum oriens of the hippocampus following 
experimental challenge with brain homogenate from patient NL-VV. D) PrP-labeled plaque-like-deposits in the corpus callosum of a HuVV 
mouse inoculated with brain homogenate from patient UK-VV; inset: Thioflavin-S (Sigma, Gillingham, UK) staining of amyloid, viewed under 
ultraviolet light in a HuVV mouse challenged with brain homogenate from patient UK-VV. HuVV and HuMV, transgenic mice expressing 
human PrP gene sequence coding for the valine-homozygous and methionine/valine-heterozygous codon 129 genotypes, respectively; 
NL-VV and UK-VV, patients from the Netherlands and United Kingdom, respectively, who had VPSPr and the valine-homozygous codon 
129 genotype; PrP, prion protein; VPSPr, variably protease-sensitive prionopathy. Scale bars indicate 25 μm.
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the 2 patients with codon 129VV provided evidence of 
transmission. This low rate of transmission may be due to 
low levels of PrPres in the brain homogenates that were in-
oculated, or it could be that the PrP genotype plays a role 
in transmission of disease.
Prion disease propagation involves the aggregation of 
abnormal PrP that acts as a template for further aggrega-
tion within the brain, a process termed seeding (21,22). 
The spread of PrP within the brain appears to occur in 
cell-to-cell fashion in well-defined neuroanatomic path-
ways (23), the mechanisms of which are yet to be elu-
cidated despite extensive studies. Prion diseases have 
the potential to be transmissible between persons, a fact 
that raises public health concerns, particularly regarding 
vCJD. Assessing the risk for transmission is a challenge 
because of the varied nature of prion diseases and con-
flicting evidence over the mechanisms of transmission. 
Risk assessment is made even more complicated by the 
existence of prion disease models in which negligible 
amounts of PrPres are associated with high infectivity ti-
ters in vivo (24) and also of models in which PrPres in the 
form of amyloid plaques develops in the absence of clini-
cal disease or spongiform changes (25).
It could be argued that the observation of small 
plaque-like amyloid deposits in the brains of mice with no 
neurologic signs of disease after the inoculation of brain 
homogenates prepared from patients with VPSPr does not 
indicate disease transmission. Instead, the deposits could 
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Figure 4. Neuropathology in transgenic mice following inoculation with brain homogenate prepared from a postmortem sample from a person 
with VPSPr. A–C) Immunohistochemistry for the PrP, showing small granular and microplaque-like deposits within the CA3 region of the 
hippocampus of a HuVV mouse challenged with VPSPr inoculum prepared from patient UK-VV. Differential staining was observed in this 
mouse by using the following PrP antibodies: Purified (3F4) (Cambridge Bioscience, Cambridge, UK) (A); Prion Protein Monoclonal Antibody 
(12F10) (Bioquote Ltd, York, UK) (B); and mAb 6H4 (Prionics AG, Schlieren, Switzerland) (C). D) Molecular layer of the cerebellum of a 
person with VPSPr, showing microplaque deposits stained with monoclonal antibody 3F4. HuVV, transgenic mouse expressing human PrP 
gene sequence coding for the valine-homozygous codon 129 genotype; PrP, prion protein; UK-VV, patient from the United Kingdom who had 
VPSPr and the valine-homozygous codon 129 genotype; VPSPr, variably protease-sensitive prionopathy. Scale bars indicate 25 μm.
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indicate an amyloid seeding phenomenon akin to that ob-
served following the experimental inoculation of primates 
with brain tissue from patients with Alzheimer disease 
(26). In those experiments, amyloid β seeding occurred 
in the primate brain in the absence of any clinical signs. 
Precedence of this phenomenon in prion disease has been 
set by Piccardo et al. (27), who showed similar results 
in a mouse model system of prion disease transmission. 
However, in our study, the brain of 1 mouse exhibited 
intensely stained, small, round granules within the hippo-
campus in addition to the plaque-like deposits (Figure 4). 
These small granules are reminiscent of the microplaques 
found in brain tissue of humans with VPSPr (4,5). Fur-
thermore, with 4 PrP antibodies, the microplaque deposits 
in the mouse brain showed the same pattern of differential 
immunoreactivity as that in the brain of patients with VP-
SPr (5,6,17). Moreover astrocytosis in the vicinity of the 
microplaques was also observed in this mouse (Figure 
5). This type of astrocytic response is observed in all our 
model systems of transmissible prion disease, but is ab-
sent from the nontransmissible forms of PrP (i.e., amyloid 
plaques in absence of clinical disease), suggesting that 
this single mouse may represent a transmission of infec-
tion rather than a consequence of seeding of inoculum 
(25,28). Second passage in the same mouse line will be 
required to prove this interpretation, but such a study will 
take an additional 3 years to complete.
Although understanding the mechanisms of transmis-
sion is an interesting facet of this study, our primary finding 
is that VPSPr is capable of transmission to transgenic mice 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 12, December 2014 1977
Figure 5. Gliosis in transgenic mice following inoculation with brain homogenate prepared from a postmortem sample from a person with variably 
protease-sensitive prionopathy. A) Immunohistochemical staining for GFAP in the hippocampus of a HuVV mouse showing microplaque-like 
deposits. Arrows indicate areas of reactive astrocytosis. B) A serial section from the same HuVV mouse immunolabeled for PrP by using 
monoclonal antibody (Purified [3F4], Cambridge Bioscience, Cambridge, UK). C) Immunohistochemical staining for GFAP in the hippocampus 
of a HuVV mouse showing plaque-like deposits. No reactive astrocytosis is seen in the vicinity of plaques. D) A serial section from the same 
HuVV mouse immunolabeled for PrP by using monoclonal antibody 3F4. GFAP, glial fibrillary acid protein; HuVV, transgenic mouse expressing 
human PrP gene sequence coding for the valine-homozygous codon 129 genotype; PrP, prion protein. Scale bars indicate 50 μm.
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expressing PrP, albeit at extremely low levels compared with 
those of other transmissible prion diseases (e.g., sCJD and 
vCJD). We demonstrate that VPSPr is a disease with biologi-
cal properties distinct from those of sCJD and with a limited, 
but not negligible, potential for infectivity. These results 
demonstrate the importance of continuing surveillance to 
fully uncover the growing spectrum of human prion diseases.
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